A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

New narcolepsy treatments are being tested in the clinic, and recently, some of them have made promising strides. How far ...

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) shares rose 3.5% following the announcement of encouraging Phase 3 trial results for its investigational narcolepsy treatment, oveporexton. The Japanese ...

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

NLS Pharmaceutics Unveils Promising Narcolepsy Treatment TipRanks Nov. 18, 2024, 07:59 AM ...

Nootropics are substances that enhance cognitive performance through various mechanisms, including cholinergic, glutamatergic ...

The Breakthrough Therapy designation for AXS-12 for the treatment of cataplexy in narcolepsy was supported by the positive results from the Phase 2 CONCERT study, a randomized, double-blind ...

On October 16, 2024, LUMRYZ was additionally approved as a once-at-bedtime treatment for cataplexy or EDS in patients 7 years of age and older with narcolepsy.

NLS Pharmaceutics Unveils Promising Narcolepsy Treatment November 18, 2024 — 08:59 am EST Written by TipRanks Auto-Generated Newsdesk for TipRanks -> ...